CD4 and skin basal cell carcinoma: Remarkably, the application of vismodegib may even lead to an upregulation of MHC-I on BCC tumor cells and an increased infiltration of CD4+, CD8+, and HLA-DR-class II-positive cells like macrophages within the tumor cell nests (35).